Respiratory News and Research

RSS

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

ILiAD Biotechnologies, LLC, the French National Institute of Health and Medical Research subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore and National University of Ireland Maynooth.

9 Jan 2014

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

The World health Organization calls depression "the leading cause of disability worldwide," causing more years of disability than cancer, HIV/AIDS, and cardiovascular and respiratory diseases combined.

8 Jan 2014

Forest Laboratories enters into definitive agreement to acquire Aptalis

Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.

8 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice University's Baker Institute for Public Policy and the University of Texas MD Anderson Cancer Center.

7 Jan 2014

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Research from the National Institute of Respiratory Diseases informs that besides smoking, there are other factors associated to the development of lung cancer such as the smoke from burning lumber and coal, as well as pollutant particles.

7 Jan 2014

Clinical features not sufficiently pathognomonic in pneumonia

Clinical signs and symptoms are not sufficiently reliable to distinguish the different etiologies of pneumonia, Dutch researchers report.

6 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

People with severe mental illness may have higher risk for substance use

People with severe mental illness such as schizophrenia or bipolar disorder have a higher risk for substance use, especially cigarette smoking, and protective factors usually associated with lower rates of substance use do not exist in severe mental illness, according to a new study funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

5 Jan 2014

Study explores safety and efficacy of scoop and run approach in Philadelphia

A new study from the Perelman School of Medicine at the University of Pennsylvania has found no significant difference in adjusted overall survival rates between gunshot and stabbing (so-called penetrating trauma injuries) victims in Philadelphia whether they were transported to the emergency department by the police department or the emergency medical services division of the fire department.

3 Jan 2014

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

Scientists discover new class of cells expressing olfactory receptors in human airways

Your nose is not the only organ in your body that can sense cigarette smoke wafting through the air. Scientists at Washington University in St. Louis and the University of Iowa have showed that your lungs have odor receptors as well.

3 Jan 2014

Blood conservation strategy during AVR can reduce costs, complications

Incorporating a blood conservation strategy (BCS) during aortic valve replacement (AVR) can reduce the likelihood of transfusion-related complications, as well as reduce blood-product utilization, according to a study in the January 2014 issue of The Annals of Thoracic Surgery.

2 Jan 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

Personalized asthma strategies needed to tackle comorbidities

Results from a German national health survey indicate that asthma patients with multiple comorbidities are at increased risk for unplanned hospital admissions.

31 Dec 2013

New technique could help researchers unlock the secrets of respiratory syncytial virus

By the time they're two, most children have had respiratory syncytial virus and suffered symptoms no worse than a bad cold. But for some children, especially premature babies and those with underlying health conditions, RSV can lead to pneumonia and bronchitis - which can require hospitalization and have long-term consequences.

30 Dec 2013

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme, a Sanofi company, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.

30 Dec 2013

Consumption of nuts promotes health and longevity, finds study

In a study published November 20, 2013 in the New England Journal of Medicine1, researchers looked at the association of nut consumption with total and cause-specific mortality among 76,464 women in the Nurses' Health Study and 42,498 men in the Health Professionals Follow-up Study. Consumption of nuts, including tree nuts (such as pistachios, almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, and walnuts), was inversely associated with total mortality in both men and women, independent of other predictors for death.

28 Dec 2013

Respiratory News and Research

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

Forest Laboratories enters into definitive agreement to acquire Aptalis

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Clinical features not sufficiently pathognomonic in pneumonia

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

People with severe mental illness may have higher risk for substance use

Study explores safety and efficacy of scoop and run approach in Philadelphia

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Scientists discover new class of cells expressing olfactory receptors in human airways

Blood conservation strategy during AVR can reduce costs, complications

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Personalized asthma strategies needed to tackle comorbidities

New technique could help researchers unlock the secrets of respiratory syncytial virus

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Consumption of nuts promotes health and longevity, finds study

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News